News | February 28, 2022
Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The transaction as well as the open offer is expected to be completed by June this year.
The sale is expected to close in the first quarter of 2022
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
